US5135480A - Transdermal drug delivery device - Google Patents

Transdermal drug delivery device Download PDF

Info

Publication number
US5135480A
US5135480A US07/617,945 US61794590A US5135480A US 5135480 A US5135480 A US 5135480A US 61794590 A US61794590 A US 61794590A US 5135480 A US5135480 A US 5135480A
Authority
US
United States
Prior art keywords
electrode
skin
transdermal device
drug
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/617,945
Inventor
Yvonne B. Bannon
John Corish
Owen I. Corrigan
Joseph G. Masterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Transdermal Ltd
Original Assignee
Elan Transdermal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Transdermal Ltd filed Critical Elan Transdermal Ltd
Application granted granted Critical
Publication of US5135480A publication Critical patent/US5135480A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432Anode and cathode
    • A61N1/044Shape of the electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432Anode and cathode
    • A61N1/0436Material of the electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Definitions

  • This invention relates to a device for the transdermal delivery of drugs and, in particular, to an electrode for use in a transdermal device which includes means for assisting or enhancing and controlling drug transport to the systemic circulation.
  • Transdermal administration means that the drug may be introduced into the systemic circulation without initially entering the portal circulation where it may be metabolized into a pharmacologically inactive form (first pass effect).
  • first pass effect For drugs that are normally taken orally, administration through the skin can eliminate factors such as pH changes and food intake that influence gastrointestinal absorption.
  • One of the most important advantages of the transdermal route is that it provides constant and continuous absorption of the drug, thus keeping blood levels within the "therapeutic window".
  • oral administration is often associated with variable absorption with blood levels sometimes rising to toxic levels or falling to subtherapeutic levels.
  • the transdermal route is, therefore, a suitable route for the administration of very potent drugs, drugs with short half lives and low therapeutic indices or drugs which are subject to significant first pass effects.
  • Transdermal administration may allow rapid termination of drug input should side effects occur, and it increases patient compliance.
  • the route is, however, clearly not suitable for drugs that seriously irritate or sensitize the skin, and for passive administration is restricted to drugs of suitable molecular configuration.
  • aprotic solvents such as dimethylsulfoxide (DMSO), Azone (Trade Mark) and surfactants (Astley and Levine (1976) J. Pharm. Sci. 65, 210-215; Stoughton and McClure Drug Dev. Ind. Pharm. (1983) 9, 725-744).
  • a transdermal delivery device In order that a transdermal delivery device may control the rate of penetration of the drug through the skin, it must release the drug at a rate which is less than that at which it can permeate the skin. Under these conditions, the more readily the drug is released from the drug delivery system, the higher the rate of transdermal absorption. The rate of drug release depends on whether the drug molecules are suspended or dissolved in the vehicle and on the interfacial partition coefficient of the drug between the delivery system and the skin.
  • transdermal drug delivery systems have been developed and are currently in use.
  • the drugs incorporated into these systems include nitroglycerin, which has been used for the treatment and prevention of angina pectoris, scopolamine for the treatment of motion sickness, the antihypertensive, clonidine and steroid hormones such as estradiol.
  • These devices typically contain the active constituent dispersed or suspended in a reservoir: its rate of release is controlled either by matrix diffusion or by its passage through a controlling membrane.
  • the skin consists of three distinct layers; the epidermis, the dermis and subcutaneous fat.
  • the outermost layer of the epidermis, the stratum corneum, is generally accepted to be the rate limiting barrier to drug penetration.
  • Hydration is one of the most important factors in skin penetration and may increase the absorption of substances that penetrate the skin Behl, C. R. et al (1983) J. Pharm. Sci., 72, 79-82. Hydration results from water used in the preparation of the transdermal device.
  • the mobility of water molecules per se within the hydrated stratum corneum is crucial to the permeability of water soluble substances because they are very probably dissolved within this absorbed water.
  • the permeability of water-soluble substances through the stratum corneum likewise, depends on the mobility of water molecules surrounding the solute, Idson, B. J. (1975) Pharm. Sci., 64, 901-924.
  • the rate of percutaneous absorption can be affected by the oil/water partition coefficient, the polarity of the drug and its degree of ionization, its solubility characteristics, molecular weight, volatility, concentration and the nature of the drug vehicle.
  • the rate of percutaneous absorption is influenced by the temperature and increases as the temperature is raised. An increase in temperature may be effected by occluding the absorption site or by application of an absorption enhancer such as DMSO or a surfactant.
  • an absorption enhancer such as DMSO or a surfactant.
  • Anatomical differences in penetration rates seem to depend largely on the thickness of the stratum corneum, with rates increasing in the following anatomical order: plantar; anterior forearm; instep; scalp; scrotum; and posterior auricular.
  • Iontophoresis is the process of moving ions into surface tissues with the aid of an electrical current, Boone, D. C. (1982) in "Clinics in Physical Therapy: Electrotherapy", Ed. Wolf, S. L., Ch. 5, p 99-121.
  • the technique was discovered nearly a century ago, but it is only in recent years that much interest has been shown in it as a method of local drug administration of ions; its chief proponents are to be found in the disciplines of dermatology, dentistry and otolaryngology.
  • Transdermal devices are known from Patent Publication GB 2 104 388A and also from U.S. Pat. Nos. 4,557,723, 4,622,031 and 4,640,689.
  • all of the devices disclosed in the aforementioned four documents are applied to the skin by adhesive means.
  • the use of adhesive at the site of application of a drug which is to be administered by the transdermal route can cause severe irritation which may necessitate discontinuing such transdermal treatment.
  • the irritation observed is frequently far more severe than the irritation caused by the drug itself which is sometimes observed at the site of application of a transdermal device.
  • the invention provides an electrode for use in a transdermal device, said electrode comprising a first surface adapted for contact with human skin and through which a drug substance contained in the electrode may pass to the skin under the influence of an iontophoretic or electro-osmotic force and a second surface remote from said skin-contacting surface which is electrically conducting and which is adapted for contact with an electrical source in said transdermal device, said electrode having a surface area in contact with the skin, in use, which is in the range 0.1-30 cm 2 , said drug being dissolved or dispersed in a hydrophilic medium in said electrode and said drug concentration being in the range 0.1 to 15% (w/v) based on the hydrophilic medium, and said second surface of said electrode being drug impermeable.
  • the hydrophilic medium is a gel material which is formed into a disc, one major surface of said disc defining said skin-contacting surface of said electrode and said other major surface of said disc having an electrically conducting material adhered thereto and defining said second surface of said electrode.
  • the disc of hydrophilic gel material may have a drug permeable membrane attached to said one major surface and defining said skin-contacting surface of said electrode and a layer of aluminium or platinum foil attached to said other major surface and defining said second surface of said electrode.
  • the hydrophilic medium is a biocompatible polymer or polymeric gel of suitable rigidity and conductance and having the drug distributed therethrough.
  • a wide range of natural and/or synthetic polymeric materials or gelling agents or mixtures thereof may be used to form the hydrophilic medium of the transdermal device according to the invention.
  • Such materials include agar gel, karaya gum gel, polyoxyethylene-polyoxypropylenes such as Pluronic F68 (Pluronic F68 is a Trade Mark) and Pluronic F127 (Pluronic F127 is a Trade Mark), gelatin, sodium carboxymethylcellulose, poly(ethylene oxide) polymers such as Macrogol (Macrogol is a Trade Mark), methylcellulose, carboxyvinyl polymers crosslinked with allyl sucrose such as Carbopol (Carbopol is a Trade Mark) and polyacrylamide gels or mixtures thereof.
  • agar is synonymous with "agar-agar”.
  • the gelling agents may be based on aqueous solvents and co-solvents.
  • the co-solvents include, for example, alcohols such as ethanol, polyols such as glycerol, ethylene glycol and propylene glycol, dimethylformamide, dimethylsulfoxide and other aqueous miscible co-solvents.
  • the reservoir may also include suitable antimicrobial, antifungal and other pharmaceutical excipients secundum artem.
  • Suitable antimicrobial and antifungal agents/preservatives include benzalkonium chloride, cetrimide (cetyltrimethylammonium bromide), benzoic acid, benzyl alcohol, Parabens (Trade Mark for the methyl-, ethyl-, propyl- and butyl- esters of para-hydroxybenzoic acid), chlorhexidine, chlorobutanol, phenylmercuric acetate, borate and nitrate, potassium sorbate, sodium benzoate, sorbic acid and thiomersal (mercurithiosalicylate) or a mixture thereof.
  • the hydrophilic medium may also include an anti-oxidant.
  • Preferred anti-oxidants include sodium metabisulphite, butylated hydroxyanisole and butylated hydroxytoluene or a mixture thereof.
  • the hydrophilic medium may also include a pH-controlling agent.
  • Preferred pH-controlling agents include citric acid and sodium citrate.
  • the hydrophilic medium may also include a plasticizer.
  • Suitable plasticizers include diethylphthalate, dibutylphthalate and tributylcitrate or a mixture thereof.
  • the hydrophilic medium may also include a surfactant.
  • Suitable surfactants include sodium lauryl sulphate, diethylene glycol monostearate, propylene glycol monostearate, polyethylene glycols as sold under the Trade Mark MACROGOL, polysorbates and polyvinyl alcohol or a mixture thereof.
  • the hydrophilic medium may also include a penetration enhancer.
  • Suitable penetration enhancers include dimethylsulfoxide, N,N-dimethylacetamide, N,N-dimethylformamide, 2-pyrrolidone, N-methyl-2-pyrrolidone and 1-dodecyl azacyclo-heptan-2-one or a mixture thereof.
  • the hydrophilic medium may also include a humectant.
  • a particularly preferred humectant is glycerol for use in a high humidity environment.
  • hydrophilic medium may also include a local anaesthetic.
  • Suitable local anaesthetics include lidocaine, benzocaine, lignocaine, methocaine, butylaminobenzoate and procaine or a mixture thereof.
  • the preparation would include a local anaesthetic mainly to suppress irritation at the site of application thereof caused by the drug.
  • the hydrophilic medium may include a rubefacient.
  • rubefacients include camphor and menthol or a mixture thereof and other locally acting peripheral vasodilators.
  • the electrode according to the invention will normally have a contact area less than 10 cm 2 .
  • the essential components of the electrical circuit including the electrode hereinafter referred to also as said first electrode are a means of adjusting the current, a means of indicating the successful operation of the device, i.e. an indicator light to show that the current is in the required range for the correct administration of the particular drug and a second electrode, which may be a counter electrode, which in use will be situated at a different site on the skin to said first electrode.
  • the counter electrode will comprise a suitable metal or polymer such as a conductive resin or rubber and may contain a suitable conducting gel and/or an adhesive.
  • the second electrode may also comprise an electrode of the type defined for said first electrode. Accordingly, the device incorporating the electrode according to the invention may be used to administer two drugs simultaneously by the transdermal route. When it is desired to administer two drugs of opposite charge, the first and second electrodes must be housed in chambers of opposite polarity.
  • the first electrode and the electrical source will be housed in a single unit which may also preferably include an LCD (liquid crystal display) and a control circuit.
  • the LCD may display current, voltage and timing readings, as required.
  • the exterior surface of the unit will, therefore, simulate the face of a time piece.
  • the unit may include an ammeter and preferably a voltage adjuster.
  • the control circuit may also include a galvanostat which regulates the current and maintains the current constant despite varying resistance of the skin.
  • the power supply will suitably comprise conventional miniature or "light-weight" batteries. For example, conventional sheet batteries and microbatteries may be used.
  • the unit may also include a timing circuit which will activate the device at selected intervals or give a signal in the form of a bleep which will prompt the user to activate the device at selected intervals of time.
  • the device can also be used for continuous administration of a drug and for continuous assisted drug transport.
  • the current used can be in the region of 0.01-10 mA.
  • the device can suitably operate at 0.5 mA at 10-20 volts.
  • the current may be constant, variable or pulsed.
  • the transdermal device includes a support means for attaching the device to a limb or appendage of the body.
  • a support means is suitably in the form of a strap or bracelet, more particularly a wrist watch strap or bracelet.
  • a hollow bracelet In place of a strap one may use a hollow bracelet. When a hollow bracelet is used the lead from the power supply to the counter electrode would be housed in the interior of the bracelet.
  • the second or counter electrode may be located in the bracelet or strap at a point distant from the first electrode or, alternatively, the two electrodes may be located adjacent to one another but separated by an insulating material.
  • drug as used herein embraces most pharmacologically active substances and also nutritional supplements such as vitamins and electrolytes.
  • suitable pharmacologically active substances for use as the drug in the electrode according to the invention include, for example, clonidine or a salt thereof, insulin, morphine, nicotine, orcipreniline or a salt thereof, salbutamol or a salt thereof, sodium chromoglycate and the peptide desmopressin. It will be appreciated that many drugs are actually administered in the form of a pharmaceutically acceptable salt.
  • the device incorporating the electrode according to the invention may be used to administer two drugs simultaneously by the transdermal route.
  • An example of drugs which may be suitably administered in this way are a combination of orcipreniline sulphate or salbutamol and sodium chromoglycate in the treatment of asthma.
  • Suitable concentrations for the preferred drugs for use in the electrode according to the invention are:
  • orcipreniline 0.1-20% (w/v) based on the hydrophilic medium
  • a particular advantage of the present transdermal device is that the electrode incorporating the drug reservoir defined by said hydrophilic medium forms an integral unit which can be discarded once the drug supply is used up.
  • the electrode incorporating the drug reservoir defined by said hydrophilic medium forms an integral unit which can be discarded once the drug supply is used up.
  • the hydrophilic gel medium used in the electrode according to the invention is biocompatible, stable, easy to handle and compatible with the conducting material of the electrode.
  • FIG. 1a is a schematic representation of a transdermal device incorporating an electrode according to the invention
  • FIG. 1b is a schematic representation of the electrode according to the invention.
  • FIG. 2 is a circuit diagram of the circuit employed in the transdermal device depicted in FIG. 1a;
  • FIG. 3 is a plot of in vitro nicotine release (mg) versus time (hours) for the electrode as prepared in Example 1;
  • FIG. 4 is a plot of in vitro clonidine release (mg) versus time (hours) for the electrode as prepared in Example 2;
  • FIG. 5 is a plot of in vitro salbutamol release (mg) versus time (hours) at 0.25 mA (curve a) and 0.5 mA (curve b) for the electrode as prepared in Example 3;
  • FIG. 6 is a plot of in vivo salbutamol plasma levels (ng/ml) versus time (hours) for the electrode as prepared in Example 3.
  • FIG. 7 is a plot of in vitro morphine release (mg) versus time (hours) for the electrode as prepared in Example 4.
  • a transdermal device incorporating a disposable electrode 3 according to the invention, said device 1 comprising a housing 2 for the electrode 3 (FIG. 1b) which consists of an electrically conducting layer 4 and a disc of 4% agar gel 5 in which is dispersed salbutamol at a concentration of 27.5 mg/ml and which is attached to the site of application by means of a strap 6 having at the free ends thereof the cooperating elements of a conventional clasp 7.
  • the electrode 3 is connected by a lead 8 to a source of electrical potential comprising a power supply 9, a control and timing circuit 10, an ammeter 11, a galvanostat 12 and a fixed metal electrode 13 against which is placed the conducting layer 4 of the electrode 3.
  • the power supply 9 is also connected via a lead 14 to a counter electrode 15 located adjacent the clasp 7 and which electrode 15, in use, allows the circuit to be completed when the device is applied to the skin.
  • the electrode 15 comprises a layer of a conducting gel, one major surface thereof defining a skin-contacting surface and the other major surface thereof having intimately associated thereto a metallic conducting layer.
  • the power supply 9 comprises two minature batteries (2.5 V).
  • the device 1 also contains an LCD 16 with appropriate switching arrangements which can display time, current and voltage, an audible alarm/warning device which prompts the user to activate the device by pressing an on/off button 17, and an LED (light emitting diode) to indicate satisfactory operation of the device.
  • the main components of the circuit employed in the device 1 are depicted in the circuit diagram comprising FIG. 2. Said components are as follows:
  • TC -- a timing circuit, optionally programmable and with an audible warning device
  • G a galvanostat
  • LCD a liquid crystal display for time, voltage or current, as selected
  • a nicotine-containing agar gel was prepared by dispersing 4% agar in glycerol:water (1:4) and dissolving nicotine (98-100% anhyd.;Sigma Chemicals N3876) therein so as to achieve a concentration of 55 mg/ml. While still in the liquid state, the gel so prepared was spread on a layer of aluminium foil so as to obtain an electrode according to the invention having a surface area of 8 cm 2 .
  • Example 1 was repeated except that nicotine was replaced by clonidine hydrochloride and the clonidine hydrochloride was dissolved in 4% agar gel so as to achieve a concentration of clonidine hydrochloride of 27 mg/ml.
  • the in vitro release of clonidine was measured according to the procedure of Example 1 and the release is depicted in FIG. 4 of the accompanying drawings.
  • Example 1 was repeated except that nicotine was replaced by salbutamol and the salbutamol was dissolved in a gel made from methylcellulose (0.16%) and agar (3.84%) so as to achieve a concentration of salbutamol of 27.5 mg/ml.
  • the in vitro release was measured according to the procedure of Example 1 and the release is depicted in FIG. 5 of the accompanying drawings.
  • Example 1 was repeated except that nicotine was replaced by morphine and the morphine was dissolved in 5% agar gel so as to achieve a concentration of 55 mg/ml.
  • the in vitro release was measured according to the procedure of Example 1 and the release is depicted in FIG. 7 of the accompanying drawings.
  • Example 1 was repeated except that nicotine replaced by desmopressin and the desmopressin was dissolved in a gel made from karaya gum (30%) so as to achieve a concentration of desmopressin of 3 mg/ml.
  • Example 1 was repeated except that nicotine was replaced by insulin and the insulin was solubilized in a 30% aqueous gel containing polyacrylamide (approx. 15 ⁇ 10 6 molecular weight) so as to obtain a concentration of insulin of 4 mg/ml.
  • the sodium chromoglycate electrode was prepared according to the procedure of Example 1 except that nicotine was replaced by sodium chromoglycate and the sodium chromoglycate was dissolved in 4% agar gel so as to achieve a concentration of 30 mg/ml.
  • the salbutamol electrode was prepared in accordance with Example 3 and contained a concentration of salbutamol of 27.5 mg/ml.

Abstract

A transdermal device having a detachably mounted electrode with a first surface adapted for contact with human skin and through which a drug substance contained in the electrode passes to the skin under the influence of an iontophoretic or electro-osmotic force and a second surface which is electrically conducting, the electrode has a surface area in contact with the skin, in use, in the range 0.1 to 30 cm2 and a drug dissolved or dispersed in a hydrophilic medium at a concentration in the range 0.1 to 15% (w/v) based on the hydrophilic medium.

Description

This is a continuation of copending application Ser. No. 07/071,755 filed on Jul. 9, 1987 now abandoned.
BACKGROUND OF THE INVENTION
This invention relates to a device for the transdermal delivery of drugs and, in particular, to an electrode for use in a transdermal device which includes means for assisting or enhancing and controlling drug transport to the systemic circulation.
DESCRIPTION OF THE PRIOR ART
The study of the penetration of drugs through the skin has become increasingly important in recent years. The aims of such enhanced and controlled delivery are to maximize the bioavailability of the drug, to optimize the therapeutic efficacy and to minimize side effects.
There are many potential advantages of the transdermal route over the more conventional methods of drug administration. These advantages may be summarized in the following way.
Transdermal administration means that the drug may be introduced into the systemic circulation without initially entering the portal circulation where it may be metabolized into a pharmacologically inactive form (first pass effect). For drugs that are normally taken orally, administration through the skin can eliminate factors such as pH changes and food intake that influence gastrointestinal absorption. One of the most important advantages of the transdermal route is that it provides constant and continuous absorption of the drug, thus keeping blood levels within the "therapeutic window". In contrast, oral administration is often associated with variable absorption with blood levels sometimes rising to toxic levels or falling to subtherapeutic levels. The transdermal route is, therefore, a suitable route for the administration of very potent drugs, drugs with short half lives and low therapeutic indices or drugs which are subject to significant first pass effects.
Transdermal administration may allow rapid termination of drug input should side effects occur, and it increases patient compliance. The route is, however, clearly not suitable for drugs that seriously irritate or sensitize the skin, and for passive administration is restricted to drugs of suitable molecular configuration.
Many of the drugs that are otherwise suitable for transdermal delivery do not achieve sufficiently high blood levels for pharmacological activity when administered transdermally so that it is sometimes necessary to enhance this delivery. This can be achieved by chemical means namely by the use of absorption promoters e.g. aprotic solvents such as dimethylsulfoxide (DMSO), Azone (Trade Mark) and surfactants (Astley and Levine (1976) J. Pharm. Sci. 65, 210-215; Stoughton and McClure Drug Dev. Ind. Pharm. (1983) 9, 725-744).
In order that a transdermal delivery device may control the rate of penetration of the drug through the skin, it must release the drug at a rate which is less than that at which it can permeate the skin. Under these conditions, the more readily the drug is released from the drug delivery system, the higher the rate of transdermal absorption. The rate of drug release depends on whether the drug molecules are suspended or dissolved in the vehicle and on the interfacial partition coefficient of the drug between the delivery system and the skin.
A number of transdermal drug delivery systems have been developed and are currently in use. The drugs incorporated into these systems include nitroglycerin, which has been used for the treatment and prevention of angina pectoris, scopolamine for the treatment of motion sickness, the antihypertensive, clonidine and steroid hormones such as estradiol. These devices typically contain the active constituent dispersed or suspended in a reservoir: its rate of release is controlled either by matrix diffusion or by its passage through a controlling membrane.
The release characteristics of a number of these commercially available passive systems have been investigated by many researchers, including Chien, Y. W. (1983) J. Pharm. Sci. 72, 968-70, Dasta, J. F. and Gerates, D. R. (1982) and Shaw, J. E., et al (1976) J. Invest. Dermatol. 67, 677-678. Many other drugs are at present being evaluated for their suitability for transdermal administration.
The skin consists of three distinct layers; the epidermis, the dermis and subcutaneous fat. The outermost layer of the epidermis, the stratum corneum, is generally accepted to be the rate limiting barrier to drug penetration.
Hydration is one of the most important factors in skin penetration and may increase the absorption of substances that penetrate the skin Behl, C. R. et al (1983) J. Pharm. Sci., 72, 79-82. Hydration results from water used in the preparation of the transdermal device.
The mobility of water molecules per se within the hydrated stratum corneum is crucial to the permeability of water soluble substances because they are very probably dissolved within this absorbed water. Just as diffusion in dilute aqueous solution requires cooperative motion of water molecules, the permeability of water-soluble substances through the stratum corneum likewise, depends on the mobility of water molecules surrounding the solute, Idson, B. J. (1975) Pharm. Sci., 64, 901-924.
The rate of percutaneous absorption can be affected by the oil/water partition coefficient, the polarity of the drug and its degree of ionization, its solubility characteristics, molecular weight, volatility, concentration and the nature of the drug vehicle.
Many compounds evaluated for their ability to undergo percutaneous absorption are strong to weak electrolytes. Depending on the pKa of the drug and the pH of the vehicle, such compounds exist in an equilibrium mixture of ionized and unionized species. To properly control the rate at which such electrolytes permeate the skin, it is necessary to determine the permeability coefficients of both forms of the drug. Michaels, A. S. et al (1975) A. I. Ch.E. 21, 985-996, calculated the permeabilities of the ionized forms of scopolamine and ephedrine to be 1/20th of those for the unionized forms. The permeation of the ionized drug through the skin is therefore possible and cannot be assumed to be negligible especially at pH levels at which large concentrations of ionized molecules are present, i.e., substances with low pKa values, Swarbrick, J. et al (1984) J. Pharm. Sci., 73, 1352-1355.
Other factors that affect the rate of absorption of drugs across the skin include chemical effects such as binding of the drug in the epidermis, (Zatz, J. L. (1983) Drug. Dev. Ind. Pharm., 9, 561-577 and the metabolism of the drug as it penetrates the skin, (Hadgraft, J. (1980) Int. J. Pharm., 4, 229-239, Guy, R. H. and Hadgraft J. (1982) Int. J. Pharm., 11, 187-197. The rate of percutaneous absorption is influenced by the temperature and increases as the temperature is raised. An increase in temperature may be effected by occluding the absorption site or by application of an absorption enhancer such as DMSO or a surfactant.
Anatomical differences in penetration rates seem to depend largely on the thickness of the stratum corneum, with rates increasing in the following anatomical order: plantar; anterior forearm; instep; scalp; scrotum; and posterior auricular.
The technique of iontophoresis has been used on a limited scale in medical therapy. Iontophoresis is the process of moving ions into surface tissues with the aid of an electrical current, Boone, D. C. (1982) in "Clinics in Physical Therapy: Electrotherapy", Ed. Wolf, S. L., Ch. 5, p 99-121. The technique was discovered nearly a century ago, but it is only in recent years that much interest has been shown in it as a method of local drug administration of ions; its chief proponents are to be found in the disciplines of dermatology, dentistry and otolaryngology. It is a safe, well documented method of introducing ions or polar substances into the skin by the application of a direct current between two electrodes placed on the skin of the patient e.g. pilocarpine, local anaesthetics, anti-virals (Gibson, L. W. and Cooke R. E. (1959) Pediatrics, 23, 545-549; Bridger M. W. M. et al, (1982) J. Med. Eng. Tech., 6, 62-64; Ramsden R. T. (1977) J. Laryngology and Otology., 91, 779-785; Johnson, C. and Shuster, S. (1970 ) British J. Dermatol., 83, 367-379; Siddiqui, 0. et al (1985) J. Pharm. Pharmacol., 37, 732-735. One advantage claimed for iontophoresis as a technique for drug administration is that systemic toxicity is virtually eliminated, since only a small amount of drug is delivered. (Gangarosa L. P. et al (1978) J. Pharm. Sci., 67, 1439-1443).
Transdermal devices are known from Patent Publication GB 2 104 388A and also from U.S. Pat. Nos. 4,557,723, 4,622,031 and 4,640,689. However, all of the devices disclosed in the aforementioned four documents are applied to the skin by adhesive means. The use of adhesive at the site of application of a drug which is to be administered by the transdermal route can cause severe irritation which may necessitate discontinuing such transdermal treatment. The irritation observed is frequently far more severe than the irritation caused by the drug itself which is sometimes observed at the site of application of a transdermal device.
It is an object of the present invention to provide an electrode for use in a transdermal device wherein the transport of drugs from a reservoir for the drug, integral with the electrode, to the skin and thence to the systemic circulation is promoted and controlled by means integral with the device and capable of supplying an electric current as a driving force for said drug transport.
It is a further object of the invention to provide a transdermal device which is portable and easy to operate and which can be readily adapted to meet the special requirements particular to a given drug.
SUMMARY OF THE INVENTION
Accordingly, the invention provides an electrode for use in a transdermal device, said electrode comprising a first surface adapted for contact with human skin and through which a drug substance contained in the electrode may pass to the skin under the influence of an iontophoretic or electro-osmotic force and a second surface remote from said skin-contacting surface which is electrically conducting and which is adapted for contact with an electrical source in said transdermal device, said electrode having a surface area in contact with the skin, in use, which is in the range 0.1-30 cm2, said drug being dissolved or dispersed in a hydrophilic medium in said electrode and said drug concentration being in the range 0.1 to 15% (w/v) based on the hydrophilic medium, and said second surface of said electrode being drug impermeable.
DETAILED DESCRIPTION OF THE INVENTION
Preferably, the hydrophilic medium is a gel material which is formed into a disc, one major surface of said disc defining said skin-contacting surface of said electrode and said other major surface of said disc having an electrically conducting material adhered thereto and defining said second surface of said electrode.
The disc of hydrophilic gel material may have a drug permeable membrane attached to said one major surface and defining said skin-contacting surface of said electrode and a layer of aluminium or platinum foil attached to said other major surface and defining said second surface of said electrode.
Preferably, the hydrophilic medium is a biocompatible polymer or polymeric gel of suitable rigidity and conductance and having the drug distributed therethrough. A wide range of natural and/or synthetic polymeric materials or gelling agents or mixtures thereof may be used to form the hydrophilic medium of the transdermal device according to the invention. Such materials include agar gel, karaya gum gel, polyoxyethylene-polyoxypropylenes such as Pluronic F68 (Pluronic F68 is a Trade Mark) and Pluronic F127 (Pluronic F127 is a Trade Mark), gelatin, sodium carboxymethylcellulose, poly(ethylene oxide) polymers such as Macrogol (Macrogol is a Trade Mark), methylcellulose, carboxyvinyl polymers crosslinked with allyl sucrose such as Carbopol (Carbopol is a Trade Mark) and polyacrylamide gels or mixtures thereof. The term "agar" is synonymous with "agar-agar". The gelling agents may be based on aqueous solvents and co-solvents. The co-solvents include, for example, alcohols such as ethanol, polyols such as glycerol, ethylene glycol and propylene glycol, dimethylformamide, dimethylsulfoxide and other aqueous miscible co-solvents. The reservoir may also include suitable antimicrobial, antifungal and other pharmaceutical excipients secundum artem.
Suitable antimicrobial and antifungal agents/preservatives include benzalkonium chloride, cetrimide (cetyltrimethylammonium bromide), benzoic acid, benzyl alcohol, Parabens (Trade Mark for the methyl-, ethyl-, propyl- and butyl- esters of para-hydroxybenzoic acid), chlorhexidine, chlorobutanol, phenylmercuric acetate, borate and nitrate, potassium sorbate, sodium benzoate, sorbic acid and thiomersal (mercurithiosalicylate) or a mixture thereof.
The hydrophilic medium may also include an anti-oxidant. Preferred anti-oxidants include sodium metabisulphite, butylated hydroxyanisole and butylated hydroxytoluene or a mixture thereof.
The hydrophilic medium may also include a pH-controlling agent. Preferred pH-controlling agents include citric acid and sodium citrate.
The hydrophilic medium may also include a plasticizer. Suitable plasticizers include diethylphthalate, dibutylphthalate and tributylcitrate or a mixture thereof.
The hydrophilic medium may also include a surfactant. Suitable surfactants include sodium lauryl sulphate, diethylene glycol monostearate, propylene glycol monostearate, polyethylene glycols as sold under the Trade Mark MACROGOL, polysorbates and polyvinyl alcohol or a mixture thereof.
The hydrophilic medium may also include a penetration enhancer. Suitable penetration enhancers include dimethylsulfoxide, N,N-dimethylacetamide, N,N-dimethylformamide, 2-pyrrolidone, N-methyl-2-pyrrolidone and 1-dodecyl azacyclo-heptan-2-one or a mixture thereof.
The hydrophilic medium may also include a humectant. A particularly preferred humectant is glycerol for use in a high humidity environment.
Further the hydrophilic medium may also include a local anaesthetic. Suitable local anaesthetics include lidocaine, benzocaine, lignocaine, methocaine, butylaminobenzoate and procaine or a mixture thereof. The preparation would include a local anaesthetic mainly to suppress irritation at the site of application thereof caused by the drug.
Additionally, the hydrophilic medium may include a rubefacient. Particularly preferred rubefacients include camphor and menthol or a mixture thereof and other locally acting peripheral vasodilators.
The electrode according to the invention will normally have a contact area less than 10 cm2.
In addition to the electrical source the essential components of the electrical circuit including the electrode hereinafter referred to also as said first electrode, are a means of adjusting the current, a means of indicating the successful operation of the device, i.e. an indicator light to show that the current is in the required range for the correct administration of the particular drug and a second electrode, which may be a counter electrode, which in use will be situated at a different site on the skin to said first electrode. The counter electrode will comprise a suitable metal or polymer such as a conductive resin or rubber and may contain a suitable conducting gel and/or an adhesive. The second electrode may also comprise an electrode of the type defined for said first electrode. Accordingly, the device incorporating the electrode according to the invention may be used to administer two drugs simultaneously by the transdermal route. When it is desired to administer two drugs of opposite charge, the first and second electrodes must be housed in chambers of opposite polarity.
More especially, the first electrode and the electrical source will be housed in a single unit which may also preferably include an LCD (liquid crystal display) and a control circuit. The LCD may display current, voltage and timing readings, as required. The exterior surface of the unit will, therefore, simulate the face of a time piece. The unit may include an ammeter and preferably a voltage adjuster. The control circuit may also include a galvanostat which regulates the current and maintains the current constant despite varying resistance of the skin. The power supply will suitably comprise conventional miniature or "light-weight" batteries. For example, conventional sheet batteries and microbatteries may be used.
The unit may also include a timing circuit which will activate the device at selected intervals or give a signal in the form of a bleep which will prompt the user to activate the device at selected intervals of time. However, the device can also be used for continuous administration of a drug and for continuous assisted drug transport.
The current used can be in the region of 0.01-10 mA. For example, the device can suitably operate at 0.5 mA at 10-20 volts. The current may be constant, variable or pulsed.
In a particularly preferred embodiment, the transdermal device includes a support means for attaching the device to a limb or appendage of the body. Such a support means is suitably in the form of a strap or bracelet, more particularly a wrist watch strap or bracelet. In place of a strap one may use a hollow bracelet. When a hollow bracelet is used the lead from the power supply to the counter electrode would be housed in the interior of the bracelet.
The second or counter electrode may be located in the bracelet or strap at a point distant from the first electrode or, alternatively, the two electrodes may be located adjacent to one another but separated by an insulating material.
The term "drug" as used herein embraces most pharmacologically active substances and also nutritional supplements such as vitamins and electrolytes. Especially suitable pharmacologically active substances for use as the drug in the electrode according to the invention include, for example, clonidine or a salt thereof, insulin, morphine, nicotine, orcipreniline or a salt thereof, salbutamol or a salt thereof, sodium chromoglycate and the peptide desmopressin. It will be appreciated that many drugs are actually administered in the form of a pharmaceutically acceptable salt.
As indicated above the device incorporating the electrode according to the invention may be used to administer two drugs simultaneously by the transdermal route. An example of drugs which may be suitably administered in this way are a combination of orcipreniline sulphate or salbutamol and sodium chromoglycate in the treatment of asthma.
Suitable concentrations for the preferred drugs for use in the electrode according to the invention are:
nicotine 0.2-5% (w/v) based on the hydrophilic medium;
clonidine 2-8% (w/v) based on the hydrophilic medium;
salbutamol 1-6% (w/v) based on the hydrophilic medium;
morphine 0.4-8% (w/v) based on the hydrophilic medium;
orcipreniline 0.1-20% (w/v) based on the hydrophilic medium;
sodium chromoglycate 1-10% (w/v) based on the hydrophilic medium;
desmopressin 0.1-5% (w/v) based on the hydrophilic medium; and
insulin 0.1-1% (w/v) based on the hydrophilic medium.
A particular advantage of the present transdermal device is that the electrode incorporating the drug reservoir defined by said hydrophilic medium forms an integral unit which can be discarded once the drug supply is used up. Hence one does not experience the problem which is characteristic of certain conventional transdermal devices which are used in association with an electrode and wherein the drug reservoir only is disposable. With such devices residues of material defining the drug reservoir adhere to the electrode when the drug supply of the reservoir is exhausted. Such residues build up with time, such that the device becomes progressively less effective and it becomes increasingly difficult to transport the drug to the skin surface in use.
The hydrophilic gel medium used in the electrode according to the invention is biocompatible, stable, easy to handle and compatible with the conducting material of the electrode.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be understood from the following description of an embodiment thereof given by way of example only with reference to the accompanying drawings in which:
FIG. 1a is a schematic representation of a transdermal device incorporating an electrode according to the invention;
FIG. 1b is a schematic representation of the electrode according to the invention;
FIG. 2 is a circuit diagram of the circuit employed in the transdermal device depicted in FIG. 1a;
FIG. 3 is a plot of in vitro nicotine release (mg) versus time (hours) for the electrode as prepared in Example 1;
FIG. 4 is a plot of in vitro clonidine release (mg) versus time (hours) for the electrode as prepared in Example 2;
FIG. 5 is a plot of in vitro salbutamol release (mg) versus time (hours) at 0.25 mA (curve a) and 0.5 mA (curve b) for the electrode as prepared in Example 3;
FIG. 6 is a plot of in vivo salbutamol plasma levels (ng/ml) versus time (hours) for the electrode as prepared in Example 3; and
FIG. 7 is a plot of in vitro morphine release (mg) versus time (hours) for the electrode as prepared in Example 4.
Referring to FIG. 1a of the drawings, there is indicated generally at 1 a transdermal device incorporating a disposable electrode 3 according to the invention, said device 1 comprising a housing 2 for the electrode 3 (FIG. 1b) which consists of an electrically conducting layer 4 and a disc of 4% agar gel 5 in which is dispersed salbutamol at a concentration of 27.5 mg/ml and which is attached to the site of application by means of a strap 6 having at the free ends thereof the cooperating elements of a conventional clasp 7. The electrode 3 is connected by a lead 8 to a source of electrical potential comprising a power supply 9, a control and timing circuit 10, an ammeter 11, a galvanostat 12 and a fixed metal electrode 13 against which is placed the conducting layer 4 of the electrode 3.
The power supply 9 is also connected via a lead 14 to a counter electrode 15 located adjacent the clasp 7 and which electrode 15, in use, allows the circuit to be completed when the device is applied to the skin. The electrode 15 comprises a layer of a conducting gel, one major surface thereof defining a skin-contacting surface and the other major surface thereof having intimately associated thereto a metallic conducting layer. The power supply 9 comprises two minature batteries (2.5 V). The device 1 also contains an LCD 16 with appropriate switching arrangements which can display time, current and voltage, an audible alarm/warning device which prompts the user to activate the device by pressing an on/off button 17, and an LED (light emitting diode) to indicate satisfactory operation of the device.
The main components of the circuit employed in the device 1 are depicted in the circuit diagram comprising FIG. 2. Said components are as follows:
TC -- a timing circuit, optionally programmable and with an audible warning device;
PS -- a power supply with reversible polarity;
A -- an ammeter;
G -- a galvanostat;
SS -- a selective switch;
LCD -- a liquid crystal display for time, voltage or current, as selected;
LED -- a visible signal of satisfactory operation of the device.
The invention will be further illustrated by the following Examples.
EXAMPLE 1
A nicotine-containing agar gel was prepared by dispersing 4% agar in glycerol:water (1:4) and dissolving nicotine (98-100% anhyd.;Sigma Chemicals N3876) therein so as to achieve a concentration of 55 mg/ml. While still in the liquid state, the gel so prepared was spread on a layer of aluminium foil so as to obtain an electrode according to the invention having a surface area of 8 cm2.
In vitro release of nicotine from the electrode so prepared was determined in a glass, custom built diffusion cell based on the Franz cell (Franz T. J. (1975) J. Invest. Dermatol., 64, 190). Full thickness abdominal skin (approx. 4 cm×15 cm) taken from cadavers within 48 hours post mortem was used in the in vitro characterisation as the transport membrane. The stratum corneum and epidermis (SCE) were separated from the other skin layers using the method of A. M. Kligman and E. Christophers (Archives Dermatology (1963) Vol. 88, pages 702-705). The nicotine transported through the membrane was analysed using a Pye Unicam SP 200 (Trade Mark) uv/vis spectrophotometer and by reverse phase HPLC. The nicotine release is depicted in FIG. 3 of the accompanying drawings.
EXAMPLE 2
Example 1 was repeated except that nicotine was replaced by clonidine hydrochloride and the clonidine hydrochloride was dissolved in 4% agar gel so as to achieve a concentration of clonidine hydrochloride of 27 mg/ml. The in vitro release of clonidine was measured according to the procedure of Example 1 and the release is depicted in FIG. 4 of the accompanying drawings.
EXAMPLE 3
Example 1 was repeated except that nicotine was replaced by salbutamol and the salbutamol was dissolved in a gel made from methylcellulose (0.16%) and agar (3.84%) so as to achieve a concentration of salbutamol of 27.5 mg/ml. The in vitro release was measured according to the procedure of Example 1 and the release is depicted in FIG. 5 of the accompanying drawings.
The release of salbutamol from the electrode so prepared was also measured in vivo in two subjects and the mean results are depicted in FIG. 6 of the accompanying drawings.
EXAMPLE 4
Example 1 was repeated except that nicotine was replaced by morphine and the morphine was dissolved in 5% agar gel so as to achieve a concentration of 55 mg/ml. The in vitro release was measured according to the procedure of Example 1 and the release is depicted in FIG. 7 of the accompanying drawings.
EXAMPLE 5
Example 1 was repeated except that nicotine replaced by desmopressin and the desmopressin was dissolved in a gel made from karaya gum (30%) so as to achieve a concentration of desmopressin of 3 mg/ml.
EXAMPLE 6
Example 1 was repeated except that nicotine was replaced by insulin and the insulin was solubilized in a 30% aqueous gel containing polyacrylamide (approx. 15×106 molecular weight) so as to obtain a concentration of insulin of 4 mg/ml.
EXAMPLE 7
Separate electrodes containing sodium chromoglycate and salbutamol, respectively, were prepared for use in a transdermal device for the simultaneous administration of said drugs by the transdermal route. The sodium chromoglycate electrode was prepared according to the procedure of Example 1 except that nicotine was replaced by sodium chromoglycate and the sodium chromoglycate was dissolved in 4% agar gel so as to achieve a concentration of 30 mg/ml. The salbutamol electrode was prepared in accordance with Example 3 and contained a concentration of salbutamol of 27.5 mg/ml.

Claims (16)

What we claim is:
1. A transdermal device suitable for long term administration of a drug substance comprising: a housing; a complete electrical circuit having a first electrode detachably mounted within a recess in said housing, said first electrode having a first surface adapted for contact with human skin and through which the drug substance contained in the first electrode may pass to the skin under the influence of an iontophoretic or electro-osmotic force and a second surface remote from said skin-contacting surface which is electrically conducting and which is adapted for contact with an electrical source in said housing such that the first electrode can be discarded and replaced by a new electrode when the drug supply substance is exhausted, said first electrode having a surface area adapted to be in contact with the skin when in use, said drug substance being dissolved or dispersed in a hydrophilic medium defining said first electrode, and said second surface of said first electrode is drug impermeable, a means for adjusting the current, means for indicating the current is in the required range for correct administration, and a second electrode which is optionally detachable for completing said electrical circuit; and a non-adhesive means for securing said device to the skin.
2. A transdermal device according to claim 1, wherein the hydrophilic medium is a gel material which is formed into a disc, one major surface of said disc defining said skin-contacting surface of said first electrode and a second major surface of said disc having an electrically conducting material adhered thereto and defining said second surface of said first electrode.
3. A transdermal device according to claim 2, wherein the disc of hydrophilic gel material has a drug permeable membrane attached to said one major surface and defining said skin-contacting surface of said first electrode and a layer of aluminium or platinum foil attached to said second major surface and defining said second surface of said first electrode.
4. A transdermal device according to claim 3, wherein the hydrophilic medium is selected from the group consisting of agar gel, karaya gum gel, a polyoxyethylene-polyoxypropylene gel, gelatin, sodium carboxymethylcellulose, a poly(ethylene oxide) polymer, methylcellulose, carboxyvinyl polymers cross linked with allyl sucrose and polyacrylamide gels or a mixture thereof.
5. A transdermal according to claim 1, wherein the hydrophilic medium contains one or more additional agents selected from the group consisting of antimicrobial agents, antifungal agents, preservatives, anti-oxidants, pH-controlling agents, plasticizers, surfactants, penetration enhancers, humectants, local anaesthetics and rubefacients.
6. A transdermal device according to claim 1, wherein the second electrode connected to said housing such that, when in use, will be situated is a different site on the skin to said first electrode.
7. A transdermal device according to claim 6, wherein the components of the electrical circuit, excluding the second electrode, are housed in a single unit, the exterior surface of said unit simulating the face of a time piece, said unit being mounted in a strap or bracelet for attachment to a limb of a body.
8. A transdermal device according to claim 7, wherein the unit includes an LCD and a galvanostat which regulates the current applied to the first electrode and maintains said current constant despite the varying resistance to the skin.
9. A transdermal device according to claim 1, wherein the drug substance is selected from the group consisting of clonidine, insulin, morphine, nicotine, orcipreniline, salbutamol, sodium chromoglycate and desmopressin or a pharmaceutically acceptable salt thereof.
10. A transdermal device according to claim 1, wherein said second electrode is also an electrode of the type as defined for said first electrode, such that the transdermal device incorporating said first and second electrodes may be used to administer two drugs simultaneously by the transdermal route.
11. A transdermal device according to claim 1, wherein the surface area of the first electrode adapted to be in contact with the skin is in the range of 0.1 to 30 cm2.
12. A transdermal device according to claim 1, wherein the drug substance has a concentration in the range of 0.1 to 15% weight/volume based on the hydrophilic medium.
13. A transdermal device comprising a housing first electrode detachably mounted to said housing and an electrical source within said housing wherein said housing is mounted in a strap or bracelet for attachment to a limb of a body, said first electrode having a fist surface with a surface area adapted for contact with human skin when in use, a drug substance dissolved or dispersed in a hydrophilic medium defining said first electrode which can pass to the skin under the influence of an iontophoretic or electroosmotic force created by said electrical source, and a second surface remote from said first surface which is drug impermeable, electrically conducting and an integral part of said first electrode, said second surface further being adapted for contact with said electrical source, and a second electrode in said strap or bracelet for connection to said electrical source and adapted to be situated at a different site on the skin to said first electrode.
14. The transdermal device according to claim 13, wherein said second electrode is also an electrode of the type as defined for said first electrode, such that the transdermal device incorporating said first and second electrodes may be used to administer two drugs simultaneously by the transdermal route.
15. A transdermal device according to claim 13, wherein the surface area of the first electrode adapted to be in contact with the skin is in the range of 0.1 to 30 cm2.
16. A transdermal device according to claim 13, wherein the drug substance has a concentration in the range of 0.1 to 15% weight/volume based on the hydrophilic medium.
US07/617,945 1986-07-10 1990-11-21 Transdermal drug delivery device Expired - Lifetime US5135480A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE185486A IE60941B1 (en) 1986-07-10 1986-07-10 Transdermal drug delivery device
IE1854/86 1986-07-10
US7175587A 1987-07-09 1987-07-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US7175587A Continuation 1986-07-10 1987-07-09

Publications (1)

Publication Number Publication Date
US5135480A true US5135480A (en) 1992-08-04

Family

ID=11031295

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/617,945 Expired - Lifetime US5135480A (en) 1986-07-10 1990-11-21 Transdermal drug delivery device

Country Status (13)

Country Link
US (1) US5135480A (en)
EP (1) EP0252732B1 (en)
JP (1) JPH0626591B2 (en)
KR (1) KR950008026B1 (en)
AT (1) ATE101350T1 (en)
AU (1) AU591997B2 (en)
CA (1) CA1319578C (en)
DE (1) DE3789035T2 (en)
ES (1) ES2051270T3 (en)
IE (1) IE60941B1 (en)
NZ (1) NZ221013A (en)
PH (1) PH26087A (en)
ZA (1) ZA875002B (en)

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298257A (en) * 1987-05-01 1994-03-29 Elan Transdermal Limited Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US5302172A (en) * 1990-03-15 1994-04-12 North Carolina State University Method and composition for iontophoresis
US5322502A (en) * 1988-10-03 1994-06-21 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5345933A (en) * 1991-09-25 1994-09-13 Siemens Aktiengesellschaft Implantable medical device with a protected medication layer
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
US5362308A (en) * 1990-09-25 1994-11-08 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5387189A (en) * 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
US5427585A (en) * 1993-03-29 1995-06-27 Bettinger; David S. On-demand iontophoretic system
US5445607A (en) * 1989-10-23 1995-08-29 Theratech, Inc. Iontophoresis device and method using a rate-controlling electrically sensitive membrane
US5540654A (en) * 1994-09-02 1996-07-30 North Carolina State University Iontophoretic electrode
US5603693A (en) * 1993-09-10 1997-02-18 Asulab S.A. Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis
US5681580A (en) * 1994-05-23 1997-10-28 Samsung Electro-Mechanics Co., Ltd. Patch-type device for iontophoretic transdermal delivery of insulin
EP0813879A2 (en) * 1996-06-20 1997-12-29 Hisamitsu Pharmaceutical Co. Inc. Drug administration composition for iontophoresis
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5733255A (en) * 1995-10-18 1998-03-31 Novartis Finance Corporation Thermopile powered transdermal drug delivery device
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5780049A (en) * 1991-10-16 1998-07-14 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5798096A (en) * 1994-08-10 1998-08-25 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biocompatible hydrogel
US5798347A (en) * 1993-01-19 1998-08-25 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
WO1998056325A1 (en) * 1997-06-13 1998-12-17 Cryopreservation Technologies Cc Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5879322A (en) * 1995-03-24 1999-03-09 Alza Corporation Self-contained transdermal drug delivery device
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
US5935597A (en) * 1995-12-15 1999-08-10 Cryopreservation Technologies Cc Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
US5935598A (en) * 1996-06-19 1999-08-10 Becton Dickinson Research Center Iontophoretic delivery of cell adhesion inhibitors
US5954685A (en) * 1996-05-24 1999-09-21 Cygnus, Inc. Electrochemical sensor with dual purpose electrode
US5971722A (en) * 1997-09-05 1999-10-26 Baxter International Inc Electrochemical syringe pump having a sealed storage reservoir for a charge transfer medium
US5989409A (en) * 1995-09-11 1999-11-23 Cygnus, Inc. Method for glucose sensing
US5993848A (en) * 1995-06-09 1999-11-30 Takeda Chemical Industries, Ltd. Dissolution liquid for drug in iontophoresis
US6035234A (en) * 1995-06-02 2000-03-07 Alza Corporation Electrotransport delivery device with voltage boosting circuit
US6175763B1 (en) 1996-03-29 2001-01-16 Alza Corporation Electrotransport drug delivery device having tactile signaling means
US6284126B1 (en) 1997-03-25 2001-09-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6355025B1 (en) * 1995-06-07 2002-03-12 Alza Corporation Adjustable electrotransport drug delivery using a fixed output controller
US20020064512A1 (en) * 2000-08-25 2002-05-30 Jens Petersen Polyacrylamide hydrogel and its use as an endoprosthesis
US6432940B1 (en) 1998-06-11 2002-08-13 Endorecherche, Inc. Uses for androst-5-ene-3β, 17β-diol
US6453195B1 (en) 2001-03-19 2002-09-17 Medtronic, Inc. Closed loop drug delivery system and remote management thereof
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2002087681A2 (en) 2001-04-30 2002-11-07 Medtronic,Inc. Implantable medical device and patch system
US20030065389A1 (en) * 2000-08-25 2003-04-03 Jens Petersen Polyacrylamide hydrogel for arthritis
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems
US20040131687A1 (en) * 2002-10-04 2004-07-08 Kraft Edward R. Photokinetic delivery of biologically active substances using pulsed incoherent light
US20040138098A1 (en) * 2002-05-07 2004-07-15 Fein Seymour H. Pharmaceutical compositions including low dosages of desmopressin
US20040151962A1 (en) * 2003-01-31 2004-08-05 Paul Adams Fuel cartridge for fuel cells
US20040253299A1 (en) * 2001-07-30 2004-12-16 Cornelia Beier Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
EP1749533A1 (en) 1997-10-28 2007-02-07 Winthrop-University Hospital Metal/thiol biocides
US20070173913A1 (en) * 2003-04-15 2007-07-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for epithelial protection during photodynamic therapy
US20070185431A1 (en) * 2006-02-03 2007-08-09 Kern Dale G Galvanic Current Skin Treatment
US20070224253A1 (en) * 2005-12-21 2007-09-27 Shire Pharmaceuticals Inc. Transdermal Delivery of Meptazinol
US20080154178A1 (en) * 2006-12-01 2008-06-26 Transcutaneous Technologies Inc. Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices
US20080188778A1 (en) * 2007-02-02 2008-08-07 Yu-Yu Chen Array percutaneous therapeutic apparatus
US20090254018A1 (en) * 2005-08-24 2009-10-08 Mizuo Nakayama Electrode assembly for freezing-type iontophoresis device
US20090292333A1 (en) * 2006-02-10 2009-11-26 Electrocore, Inc. Electrical stimulation treatment of hypotension
US20090291880A1 (en) * 2008-05-21 2009-11-26 Ferring International Center S.A. Methods comprising desmopressin
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US7747324B2 (en) 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
US20100174223A1 (en) * 2007-06-27 2010-07-08 The General Hospital Corporation D/B/A Massachusetts General Hospital Method and apparatus for optical inhibition of photodynamic therapy
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US7890164B2 (en) 2005-09-15 2011-02-15 Tti Ellebeau, Inc. Iontophoresis device
US20110046578A1 (en) * 2007-03-13 2011-02-24 Biry Jean-Francois Device for the cutaneous application of substances
US8010188B2 (en) 2006-11-14 2011-08-30 Kagoshima University Drug injecting device
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US8197844B2 (en) 2007-06-08 2012-06-12 Activatek, Inc. Active electrode for transdermal medicament administration
US8386030B2 (en) 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US20140144179A1 (en) * 2010-06-22 2014-05-29 Marta Perez De La Iglesia Transdermal drug delivery bracelet
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9539302B2 (en) 2009-06-18 2017-01-10 Allergan, Inc. Safe desmopressin administration
US10137167B2 (en) 2008-05-21 2018-11-27 Ferring B.V. Methods comprising desmopressin
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US5032109A (en) * 1987-02-10 1991-07-16 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
JPH02500339A (en) * 1987-05-15 1990-02-08 ニューマン,マーティン・エッチ Ionosmotic drug supply device
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
WO1989006989A1 (en) * 1988-01-29 1989-08-10 The Regents Of The University Of California Iontophoretic non-invasive sampling or delivery device
DK0521988T3 (en) * 1990-03-30 1996-04-29 Alza Corp Device for iontophoretic drug delivery
WO1991015260A1 (en) * 1990-03-30 1991-10-17 Alza Corporation Device and method for iontophoretic drug delivery
MX9201029A (en) * 1991-03-11 1992-09-01 Alza Corp IONTOPHORETICAL SUPPLY DEVICE AND METHOD FOR MANUFACTURING THE SAME.
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
EP0776677B1 (en) * 1992-12-31 2000-03-08 Alza Corporation Electrotransport system
US6032073A (en) * 1995-04-07 2000-02-29 Novartis Ag Iontophoretic transdermal system for the administration of at least two substances
US6147102A (en) * 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
SE0103293D0 (en) * 2001-10-03 2001-10-03 Painmatcher Ab Finger electrode and support structure
US9433459B2 (en) 2010-07-13 2016-09-06 Zoll Medical Corporation Deposit ablation within and external to circulatory systems
EP2903684A4 (en) * 2012-10-01 2016-06-29 Zoll Medical Corp Deposit ablation within and external to circulatory systems
KR20150144209A (en) * 2014-06-16 2015-12-24 훼링 비.브이. Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof
JP6341777B2 (en) * 2014-06-30 2018-06-13 リプリーズ バイオファーマシューティクス,エルエルシー Pharmaceutical composition containing low dose desmopressin
JP2018042886A (en) * 2016-09-16 2018-03-22 ロレアル Portable iontophoresis device

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2493155A (en) * 1947-01-09 1950-01-03 Mine Safety Appliances Co Apparatus for treating skin diseases
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
EP0058920A1 (en) * 1981-02-23 1982-09-01 Motion Control, Inc. Bioelectrode
EP0060451A1 (en) * 1981-03-06 1982-09-22 Medtronic, Inc. Iontophoretic electrode
GB2104388A (en) * 1981-07-10 1983-03-09 Advance Kk An iontophoresis device
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4557723A (en) * 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4622031A (en) * 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4640689A (en) * 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US4731049A (en) * 1987-01-30 1988-03-15 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533230A1 (en) * 1985-09-18 1987-03-26 Ruediger Prof Dr Groening Transdermal drug forms with improved bioavailability of the active substances

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2493155A (en) * 1947-01-09 1950-01-03 Mine Safety Appliances Co Apparatus for treating skin diseases
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
EP0058920A1 (en) * 1981-02-23 1982-09-01 Motion Control, Inc. Bioelectrode
EP0060451A1 (en) * 1981-03-06 1982-09-22 Medtronic, Inc. Iontophoretic electrode
GB2104388A (en) * 1981-07-10 1983-03-09 Advance Kk An iontophoresis device
US4474570A (en) * 1981-07-10 1984-10-02 Kabushikikaisya Advance Kaihatsu Kenkyujo Iontophoresis device
US4557723A (en) * 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4622031A (en) * 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4640689A (en) * 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US4731049A (en) * 1987-01-30 1988-03-15 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
A. M. Klingman, et al. "Preparation of Isolated Sheets of Human Stratum Corneum", vol. 88, Archives Dermatol. 702 (1963).
A. M. Klingman, et al. Preparation of Isolated Sheets of Human Stratum Corneum , vol. 88, Archives Dermatol. 702 (1963). *
A. S. Michaels, et al., "Drug Permeation Through Human Skin: Theory and in Vitro Experimental Measurement", 21 A.I. Ch. E. 985 (1975).
A. S. Michaels, et al., Drug Permeation Through Human Skin: Theory and in Vitro Experimental Measurement , 21 A.I. Ch. E. 985 (1975). *
B. J. Idson, "Percutaneous Absorption", 64 Pharm. Sci. 901 (1975).
B. J. Idson, Percutaneous Absorption , 64 Pharm. Sci. 901 (1975). *
C. R. Behl, et al., "Hydration and Percutaneous Absorption IV: Influence of Hydration on n-Alknaol Permeation Through Rat Skin; Comparison With Hairless and Swiss Mice", 72 (1) J. Pharm. Sci. 79 (1983).
C. R. Behl, et al., Hydration and Percutaneous Absorption IV: Influence of Hydration on n Alknaol Permeation Through Rat Skin; Comparison With Hairless and Swiss Mice , 72 (1) J. Pharm. Sci. 79 (1983). *
D. C. Boone, "Clinics in Physical Therapy: Electrotherapy", Ed. Wolf, S. L. Ch. 5, p. 99.
D. C. Boone, Clinics in Physical Therapy: Electrotherapy , Ed. Wolf, S. L. Ch. 5, p. 99. *
J. E. Shaw, et al. "Percutaneous Absorption: Controlled Drug Delivery For Topical or Systemic Therapy", 67 J. Invest. Dermatol. 677 (1976).
J. E. Shaw, et al. Percutaneous Absorption: Controlled Drug Delivery For Topical or Systemic Therapy , 67 J. Invest. Dermatol. 677 (1976). *
J. F. Dasta, et al. "A New Twist on an Old Standby", 2 American Pharm. (1982).
J. F. Dasta, et al. A New Twist on an Old Standby , 2 American Pharm. (1982). *
J. Hadgraft, "Theoretical Aspects of Metabolism in the Epidermis" 4 Int. J. Pharm. 229 (1980).
J. Hadgraft, Theoretical Aspects of Metabolism in the Epidermis 4 Int. J. Pharm. 229 (1980). *
J. L. Zatz, "Fundamental of Transdermal Controlled Drug Administration: Physicochemixal Considerations", 9 Drug. Dev. Ind. Pharm. 561 (1983).
J. L. Zatz, Fundamental of Transdermal Controlled Drug Administration: Physicochemixal Considerations , 9 Drug. Dev. Ind. Pharm. 561 (1983). *
J. P. Astlet, et al., "Effect of Dimethyl Sulfoxide on Permeability of Human Skin In Vitro", 65 J. Pharm Sci. 210 (1976).
J. P. Astlet, et al., Effect of Dimethyl Sulfoxide on Permeability of Human Skin In Vitro , 65 J. Pharm Sci. 210 (1976). *
J. Swarbrick, et al. "Drug Permeation Through Human Skin II: Permeability of Ionizable Compounds", 73 J. Pharm. Sci. 1352 (1984).
J. Swarbrick, et al. Drug Permeation Through Human Skin II: Permeability of Ionizable Compounds , 73 J. Pharm. Sci. 1352 (1984). *
Johnson, et al. "The Patency of Sweat Ducts in Nrmal-Looking Skin" 83 British J. Dermatol. 367 (1970).
Johnson, et al. The Patency of Sweat Ducts in Nrmal Looking Skin 83 British J. Dermatol. 367 (1970). *
L. P. Gargarosa, et al. "Conductivity of Drugs Used for Iontophoresis" 67 J. Pharm. Sci. 1439 (1978).
L. P. Gargarosa, et al. Conductivity of Drugs Used for Iontophoresis 67 J. Pharm. Sci. 1439 (1978). *
L. W. Gibson, et al. "A Test For Concentration of Electrolytes in Sweat in Cystic Fibrosis of the Pancreas Utilizing Pilocarpine by Iontophoresis", 23 Pediatrics 545 (1959).
L. W. Gibson, et al. A Test For Concentration of Electrolytes in Sweat in Cystic Fibrosis of the Pancreas Utilizing Pilocarpine by Iontophoresis , 23 Pediatrics 545 (1959). *
M. W. M. Bridger, et al. "A Device For Iontophoretic Anaesthesia of the Tympanic Membrane", 6 J. Med. Eng. Tech. 62 (1982).
M. W. M. Bridger, et al. A Device For Iontophoretic Anaesthesia of the Tympanic Membrane , 6 J. Med. Eng. Tech. 62 (1982). *
O. Siddiqui, et al. "The Effect of Iontophoresis and Vehicle pH on the In-Vitro Permeation of Lignocaine Through Human Stratum Corneum" 37 J. Pharm, Pharmacol. 732 (1985).
O. Siddiqui, et al. The Effect of Iontophoresis and Vehicle pH on the In Vitro Permeation of Lignocaine Through Human Stratum Corneum 37 J. Pharm, Pharmacol. 732 (1985). *
R. B. Toughton, et al., "Azone: A New Non-toxic Enhancer of Cutaneous Penetration", 9 Drug Development and Industrial Pharmacy 725 (1983).
R. B. Toughton, et al., Azone: A New Non toxic Enhancer of Cutaneous Penetration , 9 Drug Development and Industrial Pharmacy 725 (1983). *
R. H. Guy, et al. "Percutaneous Metabolism With Saturable Enzyme Kinetics", 11 Int. J. Pharm. 187 (1982).
R. H. Guy, et al. Percutaneous Metabolism With Saturable Enzyme Kinetics , 11 Int. J. Pharm. 187 (1982). *
R. T. Ransden, "Anaesthesia of the Tympanci Membrane Using Iontophoresis" 91 J. Larynoglogy & Otology 779 (1977).
R. T. Ransden, Anaesthesia of the Tympanci Membrane Using Iontophoresis 91 J. Larynoglogy & Otology 779 (1977). *
T. J. Franz "Percutaneous Absorption of the Relevance of In Vitro Data" 64 J. Invest, Dermatol. 190 (1975).
T. J. Franz Percutaneous Absorption of the Relevance of In Vitro Data 64 J. Invest, Dermatol. 190 (1975). *
Y. W. Chien, "Comparative Controlled Skin Permeation of Nitroglycerin from Marketed Transdermal Delivery Systems", 72 (8) J. Pharm. Sci. 968 (1983).
Y. W. Chien, Comparative Controlled Skin Permeation of Nitroglycerin from Marketed Transdermal Delivery Systems , 72 (8) J. Pharm. Sci. 968 (1983). *

Cited By (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298257A (en) * 1987-05-01 1994-03-29 Elan Transdermal Limited Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US5322502A (en) * 1988-10-03 1994-06-21 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5445607A (en) * 1989-10-23 1995-08-29 Theratech, Inc. Iontophoresis device and method using a rate-controlling electrically sensitive membrane
US5302172A (en) * 1990-03-15 1994-04-12 North Carolina State University Method and composition for iontophoresis
US5334138A (en) * 1990-03-15 1994-08-02 North Carolina State University Method and composition for increased skin concentration of active agents by iontophoresis
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5362308A (en) * 1990-09-25 1994-11-08 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
US5345933A (en) * 1991-09-25 1994-09-13 Siemens Aktiengesellschaft Implantable medical device with a protected medication layer
US5780049A (en) * 1991-10-16 1998-07-14 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5874095A (en) * 1991-10-16 1999-02-23 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5948434A (en) * 1993-01-19 1999-09-07 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5824671A (en) * 1993-01-19 1998-10-20 Endorecherche Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5843932A (en) * 1993-01-19 1998-12-01 Endorcaherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5922700A (en) * 1993-01-19 1999-07-13 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5872114A (en) * 1993-01-19 1999-02-16 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5807849A (en) * 1993-01-19 1998-09-15 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5837700A (en) * 1993-01-19 1998-11-17 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5955455A (en) * 1993-01-19 1999-09-21 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5798347A (en) * 1993-01-19 1998-08-25 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5780460A (en) * 1993-01-19 1998-07-14 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5854229A (en) * 1993-01-19 1998-12-29 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5427585A (en) * 1993-03-29 1995-06-27 Bettinger; David S. On-demand iontophoretic system
US5603693A (en) * 1993-09-10 1997-02-18 Asulab S.A. Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis
WO1995009670A1 (en) * 1993-10-05 1995-04-13 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated delivery
AU688394B2 (en) * 1993-10-05 1998-03-12 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated delivery
US5387189A (en) * 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
US5681580A (en) * 1994-05-23 1997-10-28 Samsung Electro-Mechanics Co., Ltd. Patch-type device for iontophoretic transdermal delivery of insulin
US6687522B2 (en) 1994-06-24 2004-02-03 Cygnus, Inc. Device for sample of substances using alternating polarity
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US6023629A (en) * 1994-06-24 2000-02-08 Cygnus, Inc. Method of sampling substances using alternating polarity of iontophoretic current
US5798096A (en) * 1994-08-10 1998-08-25 Maloe Vnedrencheskoe Predpriyatie "Interfall" Biocompatible hydrogel
USRE38913E1 (en) * 1994-08-10 2005-12-06 Contura Sa Biocompatible hydrogel
US5540654A (en) * 1994-09-02 1996-07-30 North Carolina State University Iontophoretic electrode
US5879322A (en) * 1995-03-24 1999-03-09 Alza Corporation Self-contained transdermal drug delivery device
US6035234A (en) * 1995-06-02 2000-03-07 Alza Corporation Electrotransport delivery device with voltage boosting circuit
US20030018296A1 (en) * 1995-06-02 2003-01-23 Riddle Thomas A. Electrotransport delivery device with voltage boosting circuit
US6842640B2 (en) 1995-06-02 2005-01-11 Alza Corporation Electrotransport delivery device with voltage boosting circuit
US20050075623A1 (en) * 1995-06-02 2005-04-07 Alza Corporation Electrotransport delivery device with voltage boosting circuit
US7708731B2 (en) 1995-06-02 2010-05-04 Alza Corporation Electrotransport delivery device with voltage boosting circuit
US6355025B1 (en) * 1995-06-07 2002-03-12 Alza Corporation Adjustable electrotransport drug delivery using a fixed output controller
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5993848A (en) * 1995-06-09 1999-11-30 Takeda Chemical Industries, Ltd. Dissolution liquid for drug in iontophoresis
US6248349B1 (en) * 1995-06-09 2001-06-19 Hisamitsu Pharmaceutical Co., Inc. Dissolution liquid for drug in iontophoresis
US5989409A (en) * 1995-09-11 1999-11-23 Cygnus, Inc. Method for glucose sensing
US5733255A (en) * 1995-10-18 1998-03-31 Novartis Finance Corporation Thermopile powered transdermal drug delivery device
US5935597A (en) * 1995-12-15 1999-08-10 Cryopreservation Technologies Cc Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
US6175763B1 (en) 1996-03-29 2001-01-16 Alza Corporation Electrotransport drug delivery device having tactile signaling means
US5954685A (en) * 1996-05-24 1999-09-21 Cygnus, Inc. Electrochemical sensor with dual purpose electrode
US5961483A (en) * 1996-06-19 1999-10-05 Sage; Burton H. Iontophoretic delivery of cell adhesion inhibitors
US5935598A (en) * 1996-06-19 1999-08-10 Becton Dickinson Research Center Iontophoretic delivery of cell adhesion inhibitors
EP0813879A3 (en) * 1996-06-20 1998-10-14 Hisamitsu Pharmaceutical Co. Inc. Drug administration composition for iontophoresis
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
EP0813879A2 (en) * 1996-06-20 1997-12-29 Hisamitsu Pharmaceutical Co. Inc. Drug administration composition for iontophoresis
USRE38681E1 (en) * 1997-03-25 2005-01-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6284126B1 (en) 1997-03-25 2001-09-04 Cygnus, Inc. Electrode with improved signal to noise ratio
GB2341319B (en) * 1997-06-13 2002-02-27 Cryopreservation Tech Cc Use of compounds in the preparation of a medicament for the therapeutic treatment of a wasting syndrome
WO1998056325A1 (en) * 1997-06-13 1998-12-17 Cryopreservation Technologies Cc Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
CZ298510B6 (en) * 1997-06-13 2007-10-24 Virodene Pharmaceutical Holdings (Pty) Ltd Drug delivery device for transdermal administration of a therapeutic agent
AP1629A (en) * 1997-06-13 2006-07-11 Virodene Pharmaceutical Holdings Pty Ltd Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes.
GB2341319A (en) * 1997-06-13 2000-03-15 Cryopreservation Tech Cc Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
ES2161187A1 (en) * 1997-06-13 2001-11-16 Virodene Pharmaceutical Holdin Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
US5971722A (en) * 1997-09-05 1999-10-26 Baxter International Inc Electrochemical syringe pump having a sealed storage reservoir for a charge transfer medium
EP1749533A1 (en) 1997-10-28 2007-02-07 Winthrop-University Hospital Metal/thiol biocides
US20070027122A1 (en) * 1998-06-11 2007-02-01 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187965A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US20020187968A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
US20080161277A1 (en) * 1998-06-11 2008-07-03 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7884092B2 (en) 1998-06-11 2011-02-08 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20070027123A1 (en) * 1998-06-11 2007-02-01 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6432940B1 (en) 1998-06-11 2002-08-13 Endorecherche, Inc. Uses for androst-5-ene-3β, 17β-diol
US6670346B1 (en) 1998-06-11 2003-12-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187963A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1731157A2 (en) 1998-06-11 2006-12-13 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US8188066B2 (en) 1998-06-11 2012-05-29 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20040157812A1 (en) * 1998-06-11 2004-08-12 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7943603B2 (en) 1998-06-11 2011-05-17 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7429576B2 (en) 1998-06-11 2008-09-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187970A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
US20020187967A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6884795B2 (en) 1998-06-11 2005-04-26 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
EP2386305A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
EP2386304A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
EP2399582A1 (en) 1998-06-11 2011-12-28 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
US6964955B2 (en) 1998-06-11 2005-11-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US20020187966A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6995150B2 (en) 1998-06-11 2006-02-07 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems
US7935361B2 (en) 2000-08-25 2011-05-03 Contura A/S Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US20020064512A1 (en) * 2000-08-25 2002-05-30 Jens Petersen Polyacrylamide hydrogel and its use as an endoprosthesis
US7186419B2 (en) 2000-08-25 2007-03-06 Contura Sa Polyacrylamide hydrogel for arthritis
US8216561B2 (en) 2000-08-25 2012-07-10 Contura A/S Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflex
US20070020226A1 (en) * 2000-08-25 2007-01-25 Contura Sa Polyacrylamide Hydrogel For The Treatment of Incontinence and Vesicouretal Reflux
US7780958B2 (en) 2000-08-25 2010-08-24 Contura Sa Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux
US20030077244A1 (en) * 2000-08-25 2003-04-24 Jens Petersen Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux
US20020150550A1 (en) * 2000-08-25 2002-10-17 Jens Petersen Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US20050175704A1 (en) * 2000-08-25 2005-08-11 Contura Sa Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US7678146B2 (en) 2000-08-25 2010-03-16 Contura A/S Polyacrylamide hydrogel and its use as an endoprosthesis
US7790194B2 (en) 2000-08-25 2010-09-07 Contura A/S Polyacrylamide hydrogel as a soft tissue filler endoprosthesis
US20030065389A1 (en) * 2000-08-25 2003-04-03 Jens Petersen Polyacrylamide hydrogel for arthritis
WO2002074386A1 (en) 2001-03-19 2002-09-26 Medtronic, Inc. Closed loop drug delivery system and remote management thereof
US6453195B1 (en) 2001-03-19 2002-09-17 Medtronic, Inc. Closed loop drug delivery system and remote management thereof
US7272433B2 (en) 2001-04-30 2007-09-18 Medtronic, Inc. Transcutaneous monitor and method of use, using therapeutic output from an implanted medical device
WO2002087681A2 (en) 2001-04-30 2002-11-07 Medtronic,Inc. Implantable medical device and patch system
US20030004554A1 (en) * 2001-04-30 2003-01-02 Riff Kenneth M. Transcutaneous monitor & method of use, using therapeutic output from an implanted medical device
US20050182389A1 (en) * 2001-04-30 2005-08-18 Medtronic, Inc Implantable medical device and patch system and method of use
US20040253299A1 (en) * 2001-07-30 2004-12-16 Cornelia Beier Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
US7405203B2 (en) 2002-05-07 2008-07-29 Reprise Biopharmaceutics, Llc Pharmaceutical compositions including low dosages of desmopressin
US8143225B2 (en) * 2002-05-07 2012-03-27 Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin
US7947654B2 (en) 2002-05-07 2011-05-24 Ferring B.V. Pharmaceutical formulations
US20090005432A1 (en) * 2002-05-07 2009-01-01 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
US9919025B2 (en) 2002-05-07 2018-03-20 Ferring B.V. Pharmaceutical formulations of desmopressin
US7560429B2 (en) 2002-05-07 2009-07-14 Ferring B.V. Orodispersible dosage forms of desmopressin acetate
US7579321B2 (en) * 2002-05-07 2009-08-25 Reprise Biopharmaceutics, Llc Pharmaceutical compositions including low dosages of desmopressin
US8802624B2 (en) 2002-05-07 2014-08-12 Ferring B.V. Methods of treatment using orodispersible desmopressin pharmaceutical formulations
US7799761B2 (en) * 2002-05-07 2010-09-21 Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin
US20040138098A1 (en) * 2002-05-07 2004-07-15 Fein Seymour H. Pharmaceutical compositions including low dosages of desmopressin
US20090318665A1 (en) * 2002-05-07 2009-12-24 Ferring B.V. Pharmaceutical formulations
US20070265207A1 (en) * 2002-05-07 2007-11-15 Fein Seymour H Pharmaceutical Compositions Including Low Dosages of Desmopressin
US20080274951A1 (en) * 2002-05-07 2008-11-06 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
US9504647B2 (en) 2002-05-07 2016-11-29 Ferring B.V. Pharmaceutical formulations of desmopressin
US9220747B2 (en) 2002-05-07 2015-12-29 Ferring B.V. Methods using desmopressin acetate in orodispersible form
US20050232997A1 (en) * 2002-05-07 2005-10-20 Ferring B.V. Pharmaceutical formulations
US10307459B2 (en) 2002-05-07 2019-06-04 Ferring B.V. Pharmaceutical formulations of desmopressin
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
US20040131687A1 (en) * 2002-10-04 2004-07-08 Kraft Edward R. Photokinetic delivery of biologically active substances using pulsed incoherent light
US20090156463A1 (en) * 2002-10-04 2009-06-18 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US7854753B2 (en) 2002-10-04 2010-12-21 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US7458982B2 (en) 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
US20040151962A1 (en) * 2003-01-31 2004-08-05 Paul Adams Fuel cartridge for fuel cells
US7147955B2 (en) 2003-01-31 2006-12-12 Societe Bic Fuel cartridge for fuel cells
US20070173913A1 (en) * 2003-04-15 2007-07-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for epithelial protection during photodynamic therapy
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US10953170B2 (en) 2003-05-13 2021-03-23 Nuvaira, Inc. Apparatus for treating asthma using neurotoxin
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US8386030B2 (en) 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US20090254018A1 (en) * 2005-08-24 2009-10-08 Mizuo Nakayama Electrode assembly for freezing-type iontophoresis device
US7890164B2 (en) 2005-09-15 2011-02-15 Tti Ellebeau, Inc. Iontophoresis device
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US7747324B2 (en) 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
US20070224253A1 (en) * 2005-12-21 2007-09-27 Shire Pharmaceuticals Inc. Transdermal Delivery of Meptazinol
US20070185431A1 (en) * 2006-02-03 2007-08-09 Kern Dale G Galvanic Current Skin Treatment
US8233988B2 (en) 2006-02-10 2012-07-31 Electrocore Llc Electrical stimulation treatment of hypotension
US8483835B2 (en) 2006-02-10 2013-07-09 ElectroCore, LLC Methods and apparatus for treating anaphylaxis using electrical modulation
US8612004B2 (en) 2006-02-10 2013-12-17 ElectroCore, LLC Electrical stimulation treatment of hypotension
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US7869879B2 (en) 2006-02-10 2011-01-11 Electrocore Llc Electrical stimulation treatment of hypotension
US7725188B2 (en) 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US8204598B2 (en) 2006-02-10 2012-06-19 Electrocore Llc Methods and apparatus for treating bronchial restriction using electrical modulation
US8099167B1 (en) 2006-02-10 2012-01-17 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US20110071592A1 (en) * 2006-02-10 2011-03-24 ElectroCore, LLC Methods and apparatus for treating anaphylaxis using electrical modulation
US8010197B2 (en) 2006-02-10 2011-08-30 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US20090292333A1 (en) * 2006-02-10 2009-11-26 Electrocore, Inc. Electrical stimulation treatment of hypotension
US8010188B2 (en) 2006-11-14 2011-08-30 Kagoshima University Drug injecting device
US8062783B2 (en) 2006-12-01 2011-11-22 Tti Ellebeau, Inc. Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices
US20080154178A1 (en) * 2006-12-01 2008-06-26 Transcutaneous Technologies Inc. Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices
US20080188778A1 (en) * 2007-02-02 2008-08-07 Yu-Yu Chen Array percutaneous therapeutic apparatus
US8574205B2 (en) * 2007-03-13 2013-11-05 Dbv Technologies Device for the cutaneous application of substances
US20110046578A1 (en) * 2007-03-13 2011-02-24 Biry Jean-Francois Device for the cutaneous application of substances
US8197844B2 (en) 2007-06-08 2012-06-12 Activatek, Inc. Active electrode for transdermal medicament administration
US20100174223A1 (en) * 2007-06-27 2010-07-08 The General Hospital Corporation D/B/A Massachusetts General Hospital Method and apparatus for optical inhibition of photodynamic therapy
US9108045B2 (en) 2007-06-27 2015-08-18 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
US9375530B2 (en) 2007-08-06 2016-06-28 Allergan, Inc. Methods and devices for desmopressin drug delivery
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same
US8489192B1 (en) 2008-02-15 2013-07-16 Holaira, Inc. System and method for bronchial dilation
US8731672B2 (en) 2008-02-15 2014-05-20 Holaira, Inc. System and method for bronchial dilation
US11058879B2 (en) 2008-02-15 2021-07-13 Nuvaira, Inc. System and method for bronchial dilation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US8961508B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8808280B2 (en) 2008-05-09 2014-08-19 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US10149714B2 (en) 2008-05-09 2018-12-11 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8226638B2 (en) 2008-05-09 2012-07-24 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8821489B2 (en) 2008-05-09 2014-09-02 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9668809B2 (en) 2008-05-09 2017-06-06 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US11020448B2 (en) 2008-05-21 2021-06-01 Ferring B.V. Methods comprising desmopressin
US20090291880A1 (en) * 2008-05-21 2009-11-26 Ferring International Center S.A. Methods comprising desmopressin
US10137167B2 (en) 2008-05-21 2018-11-27 Ferring B.V. Methods comprising desmopressin
US9974826B2 (en) 2008-05-21 2018-05-22 Ferring B.V. Methods comprising desmopressin
EP3178480A1 (en) 2009-06-16 2017-06-14 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US11452731B2 (en) 2009-06-16 2022-09-27 Endorecherche, Inc. Method of treating and preventing loss of cognition
EP3682880A1 (en) 2009-06-16 2020-07-22 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US10342805B2 (en) 2009-06-16 2019-07-09 Endorecherche, Inc. Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
US11419914B2 (en) 2009-06-18 2022-08-23 Serenity Pharmaceuticals Llc Safe desmopressin administration
US9539302B2 (en) 2009-06-18 2017-01-10 Allergan, Inc. Safe desmopressin administration
US9017324B2 (en) 2009-10-27 2015-04-28 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9675412B2 (en) 2009-10-27 2017-06-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9005195B2 (en) 2009-10-27 2015-04-14 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9931162B2 (en) 2009-10-27 2018-04-03 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8777943B2 (en) 2009-10-27 2014-07-15 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US11389233B2 (en) 2009-11-11 2022-07-19 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US10610283B2 (en) 2009-11-11 2020-04-07 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9649154B2 (en) 2009-11-11 2017-05-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US11712283B2 (en) 2009-11-11 2023-08-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
US11607407B2 (en) 2010-04-13 2023-03-21 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20140144179A1 (en) * 2010-06-22 2014-05-29 Marta Perez De La Iglesia Transdermal drug delivery bracelet
US9033910B2 (en) * 2010-06-22 2015-05-19 Marta Perez De La Iglesia Transdermal drug delivery bracelet
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10548903B2 (en) 2014-03-10 2020-02-04 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm

Also Published As

Publication number Publication date
KR950008026B1 (en) 1995-07-24
NZ221013A (en) 1990-09-26
PH26087A (en) 1992-02-06
DE3789035D1 (en) 1994-03-24
EP0252732A3 (en) 1989-03-22
JPH0626591B2 (en) 1994-04-13
ZA875002B (en) 1988-03-30
EP0252732B1 (en) 1994-02-09
AU7550187A (en) 1988-01-14
IE60941B1 (en) 1994-09-07
KR880001309A (en) 1988-04-22
EP0252732A2 (en) 1988-01-13
AU591997B2 (en) 1989-12-21
CA1319578C (en) 1993-06-29
DE3789035T2 (en) 1994-07-28
JPS6329662A (en) 1988-02-08
ES2051270T3 (en) 1994-06-16
IE861854L (en) 1988-01-10
ATE101350T1 (en) 1994-02-15

Similar Documents

Publication Publication Date Title
US5135480A (en) Transdermal drug delivery device
US5167616A (en) Iontophoretic delivery method
Khan et al. Iontophoretic drug delivery: history and applications
Kalia et al. Iontophoretic drug delivery
RU2268075C2 (en) Device for electrokinetic transfer
USRE38000E1 (en) Electrokinetic drug delivery apparatus
US8328788B2 (en) Methods and systems for electrokinetic delivery of a substance
EP1448263B1 (en) Device for controlled delivery of active substance into the skin
EP0804155A1 (en) Composition and method for enhancing transdermal electrotransport agent delivery
US5713846A (en) Iontophoretic drug delivery system, including method for activating same for attachment to patient
CN107029343B (en) A kind of portable cutaneous penetration patch instrument and preparation method thereof
CA2132348C (en) User activated iontophoretic device and method for using same
US20050273047A1 (en) System and method for transdermal delivery of an anticoagulant
JP3119488B2 (en) Iontophoresis device for water-soluble steroids
AU2003271179A1 (en) Portable ion introduction unit and method for dosing medicine
Adedapo et al. Iontophoresis: Anemergingapproachtotransdermal drug delivery
Latham et al. The role of polymer electrolytes in drug delivery
LATHAM et al. DE MONTFORT UNIVERSITY, LEICESTER LE19BH, ENGLAND
Bagade et al. FUNDAMENTAL PRINCIPLE AND APPLICATIONS OF IONTOPHORESIS IN CONTEMPORARY ADVANCEMENT OF DRUG DELIVERY SYSTEM: A CRITICAL APPRAISAL
Gannu et al. Iontophoretic Drug Delivery

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12